NEXT 2022 – Redefining the Possible
March 15, 2022
Download your free copy of NEXT 2022. This report forecasts the developments, trends, and the progress being made across the rare disease landscape.
- Learn how patients are taking ownership of their own data and using new data collection platforms to control who has access and drive data-sharing accelerate diagnosis and development of new therapies
- Find out how artificial intelligence and new sequencing technologies are accelerating the rate at which rare diseases are being diagnosed
- Read how patient organizations are moving up the value chain from backing early-stage academic research to investment drug developers and even form their own drug development companies to take an active role in therapeutic development
- As year-over-year funding of rare disease drug developers increased by 28 percent 2021 to $22.9 billion, see how investment has shifted from IPOs to M&A and deal-making during the second half of the year where funding is going.
Sign up for updates straight to your inbox.